News & Updates
Filter by Specialty:
Organic pollutants found in Mediterranean diet up GDM risk
Adherence to a healthy dietary pattern, such as the Mediterranean diet (MedDiet), may reduce the risk of gestational diabetes mellitus (GDM) but appears to increase exposure to harmful chemicals, according to a Singapore study presented at ADA 2024.
Organic pollutants found in Mediterranean diet up GDM risk
01 Jul 2024
ECHELON-3: Brentuximab vedotin ticks another box on the lymphoma treatment board
A triplet regimen comprising the anti-CD30 antibody-drug conjugate (ADC) brentuximab vedotin (BV) plus lenalidomide and rituximab (R2) inches its way into the R/R DLBCL* treatment path in the prespecified interim analysis of the ECHELON-3 trial, further reinforcing the role of BV in lymphoma treatment.
ECHELON-3: Brentuximab vedotin ticks another box on the lymphoma treatment board
01 Jul 2024
Risk of death 54 percent lower with remdesivir added for hospitalized COVID-19 patients on O₂ support
The inclusion of remdesivir in the SoC is significantly associated with a 54-percent lower risk of death at day 28 among hospitalized adults with COVID-19 who require O2 support, suggests a cross-study comparison that weight-balances patients from a clinical trial with those from a real-world study
Risk of death 54 percent lower with remdesivir added for hospitalized COVID-19 patients on O₂ support
01 Jul 2024
Cognitive remediation delivers sustained improvement in schizophrenia
People with schizophrenia may benefit from cognitive remediation which offers durable improvements in both cognition and psychosocial functioning, as shown in a study.
Cognitive remediation delivers sustained improvement in schizophrenia
30 Jun 2024
Pioglitazone boosts HbA1c decrease while preventing ketone increase
In patients with type 1 diabetes (T1D) treated with SGLT2 inhibitors, such as dapagliflozin, the addition of pioglitazone helps to intensify the reduction in HbA1c and blocks the increase in plasma ketone driven by SGLT2 inhibitors, reports a study presented at ADA 2024. This enables long-term cardiovascular and renal outcome studies to be safely performed in T1D patients.
